Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Change in Receivables (2018 - 2025)

10x Genomics (TXG) has disclosed Change in Receivables for 8 consecutive years, with -$17.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 496.66% to -$17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.9 million through Dec 2025, up 229.4% year-over-year, with the annual reading at $34.9 million for FY2025, 229.4% up from the prior year.
  • Change in Receivables hit -$17.3 million in Q4 2025 for 10x Genomics, down from $90.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $90.1 million in Q3 2025 to a low of -$35.3 million in Q1 2025.
  • Historically, Change in Receivables has averaged $3.6 million across 5 years, with a median of $5.3 million in 2021.
  • Biggest five-year swings in Change in Receivables: soared 3383.84% in 2023 and later tumbled 496.66% in 2025.
  • Year by year, Change in Receivables stood at $6.8 million in 2021, then surged by 202.14% to $20.6 million in 2022, then tumbled by 46.78% to $11.0 million in 2023, then plummeted by 60.18% to $4.4 million in 2024, then crashed by 496.66% to -$17.3 million in 2025.
  • Business Quant data shows Change in Receivables for TXG at -$17.3 million in Q4 2025, $90.1 million in Q3 2025, and -$2.6 million in Q2 2025.